Impax Laboratories (MM) News - IPXLE

Empower your portfolio: Real-time discussions and actionable trading ideas.

IMPAX Provides Further Update of Progress in Filing 10-K and 10-Q and Estimates of Results

IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today provided additional information concerning its progress in filing its annual report on Form 10-K for...

IMPAX Laboratories, Inc. Agrees to Sell $75 Million of 3.5% Senior Subordinated Convertible Debentures Due 2012; Proceeds to be

IMPAX Laboratories, Inc. (Nasdaq:IPXLE) today announced that it has entered into a definitive agreement to sell $75 million aggregate principal...

IMPAX to Increase Existing Credit Facility

IMPAX Laboratories, Inc. (Nasdaq:IPXLE) announced today that it received commitments from Wachovia Bank, National Association and Wachovia Capital...

IMPAX Provides Updates on Progress to File 10-K and Related Matters

IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today reported steps taken to complete its financial closing and file its Annual Report on Form 10-K for...

CORRECTING and REPLACING IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 20

First graph, first sentence of release should read: xxx a generic version of Rimadyl(R) (Carpofen) 25, 75 and 100 mg Caplets (sted xxx a generic...

IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 2005

IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval to the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Impax Laboratories (MM) (IPXLE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPXLE News

IMPAX Provides Further Update of Progress in Filing 10-K and 10-Q and Estimates of Results

IMPAX Laboratories, Inc. Agrees to Sell $75 Million of 3.5% Senior Subordinated Convertible Debentures Due 2012; Proceeds to be

IMPAX to Increase Existing Credit Facility

IMPAX Provides Updates on Progress to File 10-K and Related Matters

CORRECTING and REPLACING IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 20

IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 2005

IPXLE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Impax Laboratories (MM) (IPXLE) News

Impax Laboratories (MM) (IPXLE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPXLE News

IMPAX Provides Further Update of Progress in Filing 10-K and 10-Q and Estimates of Results

IMPAX Laboratories, Inc. Agrees to Sell $75 Million of 3.5% Senior Subordinated Convertible Debentures Due 2012; Proceeds to be

IMPAX to Increase Existing Credit Facility

IMPAX Provides Updates on Progress to File 10-K and Related Matters

CORRECTING and REPLACING IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 20

IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 2005

IPXLE Discussion

Your Recent History